This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Abicipar pegol for wet age related macular degeneration

Abicipar pegol is an anti‐VEGF‐A therapy in clinical development for the treatment of wet age‐related macular degeneration. Wet age‐related macular degeneration is a chronic eye
disease characterised by the formation and proliferation of blood vessels in the centre of the retina (a layer of tissue in the back of the eye that senses light and sends images to the brain).
Wet age‐related macular degeneration is a leading cause of central sight loss and blindness. Current treatment options include anti‐VEGF‐A therapies which are the current standard of
care.
Abicipar pegol is a novel therapeutic approach that uses a new generation of genetically engineered proteins that exhibit highly specific and high‐affinity target protein binding. As
an anti‐VEGF‐A, it works by inhibiting the growth of immature blood vessels that grow in the retina, reducing the haemorrhaging and scarring that leads to vision impairment. Abicipar
pegol has the potential to require less frequent injections into the eye than the current standard of care, while providing equal improvements in vision. If licensed this could be an effective treatment option with greater compliance for patients with wet age‐related macular degeneration.

Download Full Article

Twitter

Related Posts

Ranibizumab as intravitreal injections is in clinical development for the treatment of diabetic retinopathy in both its proliferative and non-proliferative forms. Diabetic retinopathy, is a disease that affect the retinas and other parts of the inner eye. It is a chronic progressive condition of the retinal blood vessels due to prolonged raised blood glucose. When new blood vessels and scar tissue form on the retina causing bleeding within the eye and loss of vision, it is called proliferative diabetic retinopathy.

A cataract is any opacity of the lens, whether it is a small local opacity or a diffuse general loss of transparency. Sometimes, it can cause a significant reduction in visual acuity or a functional impairment. Cataract is the leading cause of blindness in the world. Cataract surgery is currently the only effective treatment to …

Ranibizumab is a medicinal product already available for treating a range of visual impairments in adult patients. It is injected directly into the eye and it works by preventing abnormal blood vessels from developing and growing in the eye (one of the causes of ROP) by blocking a protein called VEGF. If ranibizumab is licenced for treatment of ROP, it will be the first anti-VEGF medication to be approved for the treatment of ROP. This will potentially provide an alternative treatment to laser and surgical treatments for ROP.

There are currently very few treatment options for LHON. Most treatment methods are used to support the patient rather than cure them. Lenadogene nolparvovec is a new gene-targeted treatment intended for vision loss caused by LHON due to an alteration in a specific gene. As a genetic medicine, lenadogene nolparvovec could be a promising option …